1. Home
  2. NMG vs PRTA Comparison

NMG vs PRTA Comparison

Compare NMG & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nouveau Monde Graphite Inc.

NMG

Nouveau Monde Graphite Inc.

HOLD

Current Price

$1.91

Market Cap

671.4M

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$9.77

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMG
PRTA
Founded
2011
2012
Country
Canada
Ireland
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
671.4M
539.9M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
NMG
PRTA
Price
$1.91
$9.77
Analyst Decision
Strong Buy
Buy
Analyst Count
2
9
Target Price
$5.75
$19.00
AVG Volume (30 Days)
946.2K
399.3K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.60
Revenue
N/A
$814,000.00
Revenue This Year
N/A
$1,111.38
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$16.32
Revenue Growth
N/A
N/A
52 Week Low
$1.60
$4.32
52 Week High
$6.06
$11.80

Technical Indicators

Market Signals
Indicator
NMG
PRTA
Relative Strength Index (RSI) 40.72 42.33
Support Level $1.81 $9.66
Resistance Level $2.00 $10.11
Average True Range (ATR) 0.11 0.61
MACD -0.02 -0.19
Stochastic Oscillator 25.56 17.46

Price Performance

Historical Comparison
NMG
PRTA

About NMG Nouveau Monde Graphite Inc.

Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The Company currently operates in two segments: the Mining projects (which includes the Matawinie Mine project and the Uatnan Mining Project) and the Battery Material Plant project.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: